Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 2
1983 1
1984 3
1985 1
1986 11
1987 14
1988 10
1989 20
1990 17
1991 13
1992 15
1993 20
1994 29
1995 32
1996 52
1997 68
1998 68
1999 90
2000 89
2001 117
2002 128
2003 108
2004 111
2005 103
2006 88
2007 97
2008 82
2009 101
2010 121
2011 143
2012 128
2013 118
2014 138
2015 126
2016 140
2017 122
2018 102
2019 91
2020 128
2021 119
2022 89
2023 67
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

2,867 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L; RADIANCE Trial Investigators. Cohen JA, et al. Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3. Lancet Neurol. 2019. PMID: 31492652 Clinical Trial.
The RADIANCE phase 3 study aimed to confirm the safety and efficacy of ozanimod versus interferon beta-1a in individuals with relapsing multiple sclerosis. ...Adjusted ARRs were 0.17 (95% CI 0.14-0.21) with ozanimod 1.0 mg, 0.22 (0.18-0.26) with ozanimod 0.5 …
The RADIANCE phase 3 study aimed to confirm the safety and efficacy of ozanimod versus interferon beta-1a in individual …
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA; SUNBEAM Study Investigators. Comi G, et al. Lancet Neurol. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3. Lancet Neurol. 2019. PMID: 31492651 Clinical Trial.
The SUNBEAM study aimed to assess the safety and efficacy of ozanimod versus intramuscular interferon beta-1a in participants with relapsing multiple sclerosis. ...Adjusted ARRs were 0.35 (0.28-0.44) for interferon beta-1a, 0.18 (95% CI 0 …
The SUNBEAM study aimed to assess the safety and efficacy of ozanimod versus intramuscular interferon beta-1a in partic …
Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.
Zhang J, Shi S, Zhang Y, Luo J, Xiao Y, Meng L, Yang X. Zhang J, et al. Cochrane Database Syst Rev. 2017 Nov 27;11(11):CD010968. doi: 10.1002/14651858.CD010968.pub2. Cochrane Database Syst Rev. 2017. PMID: 29178444 Free PMC article. Review.
OBJECTIVES: To compare the efficacy, tolerability and safety of alemtuzumab versus interferon beta 1a in the treatment of people with RRMS to prevent disease activity. ...All trials compared alemtuzumab 12 mg per day or 24 mg per day versus IFN beta …
OBJECTIVES: To compare the efficacy, tolerability and safety of alemtuzumab versus interferon beta 1a in the treatment …
Nebulised interferon beta-1a for patients with COVID-19.
Peiffer-Smadja N, Yazdanpanah Y. Peiffer-Smadja N, et al. Lancet Respir Med. 2021 Feb;9(2):122-123. doi: 10.1016/S2213-2600(20)30523-3. Epub 2020 Nov 12. Lancet Respir Med. 2021. PMID: 33189160 Free PMC article. No abstract available.
Interferon beta 1a.
Pozzilli C, Koudriavtseva T. Pozzilli C, et al. Baillieres Clin Neurol. 1997 Oct;6(3):481-93. Baillieres Clin Neurol. 1997. PMID: 10101585 Review.
An improved understanding of the immunopathogenesis of multiple sclerosis (MS) has led to therapeutic attempts using immunoregulatory agents in patients with MS, including interferon beta. IFN-beta 1a has been tested in relapsing-remitting MS and its e …
An improved understanding of the immunopathogenesis of multiple sclerosis (MS) has led to therapeutic attempts using immunoregulatory agents …
Interferon beta 1a (Rebif) in relapsing remitting multiple sclerosis.
Sánchez RC, de la Fe AD, Suarez AP, Grass D, Vega TM, Canal AS, Siniscalco D, de Los Angeles Robinson Agramonte M. Sánchez RC, et al. Drug Dev Res. 2021 Aug;82(5):707-715. doi: 10.1002/ddr.21798. Epub 2021 Feb 15. Drug Dev Res. 2021. PMID: 33586209
It is imperative to evaluate the efficacy of newest, biotechnological products modifying the disease. This study was designed to evaluate the use of interferon beta 1a (Rebif) in patients with relapsing remitting MS treated at International Center for Neurolo …
It is imperative to evaluate the efficacy of newest, biotechnological products modifying the disease. This study was designed to evaluate th …
Comparative Toxicity of Interferon Beta-1a Impurities of Heavy Metal Ions.
Berillo D. Berillo D. Medicina (Kaunas). 2022 Mar 23;58(4):463. doi: 10.3390/medicina58040463. Medicina (Kaunas). 2022. PMID: 35454302 Free PMC article.
Materials and Methods: ReciGen and Rebif are pharmaceutical interferon beta-1a (IFNbeta-1a) contained in preparations that are used for parenteral administration. ...Further testing of IFNbeta-1a bioequivalence for parenteral application is nece …
Materials and Methods: ReciGen and Rebif are pharmaceutical interferon beta-1a (IFNbeta-1a) contained in prepara …
Interferon Beta-1a versus Combined Interferon Beta-1a and Oligodendrocyte-Specific FGFR1 Deletion in Experimental Autoimmune Encephalomyelitis.
Rajendran R, Rajendran V, Gupta L, Shirvanchi K, Schunin D, Karnati S, Giraldo-Velásquez M, Berghoff M. Rajendran R, et al. Int J Mol Sci. 2022 Oct 12;23(20):12183. doi: 10.3390/ijms232012183. Int J Mol Sci. 2022. PMID: 36293040 Free PMC article.
To investigate the effects of short-term treatment with s.c. IFNbeta-1a versus the combined application of s.c. IFNbeta-1a and oligodendrocyte-specific deletion of FGFR1 (Fgfr1(ind)(-/-) mice) in MOG(35-55)-induced EAE. ...These data suggest that the beneficial effe …
To investigate the effects of short-term treatment with s.c. IFNbeta-1a versus the combined application of s.c. IFNbeta-1a and …
2,867 results

Searches related to "interferon beta-1a"